Bellicum Pharmaceuticals, Inc.
(NASDAQ : BLCM)

( )
BLCM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.87%285.761.5%$877.84m
GILDGilead Sciences, Inc. -0.19%87.791.0%$684.30m
MRNAModerna, Inc. 3.15%179.000.0%$651.73m
REGNRegeneron Pharmaceuticals, Inc. 2.25%764.272.6%$499.64m
VRTXVertex Pharmaceuticals, Inc. 1.85%317.581.9%$473.10m
BIIBBiogen, Inc. 0.23%292.151.8%$407.81m
ILMNIllumina, Inc. 1.23%208.523.2%$225.94m
BMRNBioMarin Pharmaceutical, Inc. 1.44%103.694.2%$162.19m
BNTXBioNTech SE 0.63%162.630.0%$150.70m
AXSMAxsome Therapeutics, Inc. 3.85%78.161.6%$146.95m
SNSSSunesis Pharmaceuticals, Inc. -3.98%1.930.7%$134.91m
RXDXPrometheus Biosciences, Inc 165.67%95.801.4%$103.84m
MRTXMirati Therapeutics, Inc. -30.66%49.591.6%$102.08m
HALOHalozyme Therapeutics, Inc. 2.41%57.7418.4%$82.03m
NVAXNovavax, Inc. 2.62%17.2275.3%$81.88m

Company Profile

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.